Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains
Victoria L. Champion(Indiana University Health), George W. Sledge(Caris Life Sciences (United States))
Cited by 271
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
|Journal of Clinical Oncology|2001|819
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
|Clinical Cancer Research|2008|456